Business article - June 24, 2019
13 Scandinavian start-ups granted EIT Health Headstart funding
The start-ups were selected from around 50 applicants and the funding will allow the start-ups to take steps towards market launch and commercialization. The 13 start-ups represent solutions in medtech, digital health and diagnostics. They span areas from cancer diagnostics and multiparametric tests, surgical equipment, medical technologies related to Alzheimers, cancer treatment software, dental implants, […]
Financing - June 15, 2019
Ultimovacs enters the Oslo Stock Exchange
The Norwegian cancer vaccine company has raised NOK 370 million and entered the Oslo Stock Exchange on Monday 3 June 2019. Several interested parties have now become shareholders in the company, totalling approximately 1 500 shareholders, reports Oslo Cancer Cluster. “It is good for the Norwegian health industry and for Ultimovacs when national and international […]
Financing - May 27, 2019
OssDsign finish a new issue of 151.3 MSEK before listing on Nasdaq First North
With this new issue of shares OssDsign adds about 151.3 million SEK and around 2000 new owners. “It is of course very gratifying to see a great interest in OssDsign and that we have been able to both attract well renowned institutional owners and achieve a broad dispersion in our offer. The new issue of […]
Financing - May 23, 2019
Omnio receives funding from Swelife innovation programme
Omnio has developed a drug candidate based on the protein plasminogen that can counteract tooth loss. Thanks to the funding the company may now move forward even faster, states the CEO, Patric Stafshede Tooth loss Tooth loss can be caused by periodontitis, an infectious disease that causes teeth to slowly loosen by weakening the jawbone. […]
Financing - May 22, 2019
BioArctic receives 15 million EUR milestone
The company will receive a milestone payment from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD) with BAN2401 in early Alzheimer´s disease. Eisai is responsible for the clinical development of BAN2401, including this confirmatory Phase 3 study, and BioArctic is entitled […]
Financing - May 21, 2019
Athera raises 55 million SEK
The biotech company has announced the closing of new share issue, raising in total 55 million SEK from current major shareholders including Industrifonden and Östersjöstiftelsen, together with new shareholders from the Sciety network of investors. The new capital will be used for a clinical Phase 2 study and Athera aims for partnering with a larger […]
